Filtered By:
Condition: Anemia
Nutrition: Sodium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
Long ‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
ConclusionsIn patients with acute decompensated HFpEF, over 5 years of follow-up, nearly of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both ou tcomes.
Source: ESC Heart Failure - March 11, 2023 Category: Cardiology Authors: Angiza Shahim,
Marion Hourqueig,
Lars H. Lund,
Gianluigi Savarese,
Emmanuel Oger,
Ashwin Venkateshvaran,
Lina Benson,
Jean ‐Claude Daubert,
Cecilia Linde,
Erwan Donal,
Camilla Hage Tags: Original Article Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher,
Benedikt Schrage,
Giulia Ferrannini,
Lina Benson,
Javed Butler,
Juan Jesus Carrero,
Francesco Cosentino,
Ulf Dahlstr öm,
Linda Mellbin,
Giuseppe M.C. Rosano,
Gianfranco Sinagra,
Davide Stolfo,
Lars H. Lund,
Gianluigi Savares Tags: Research Article Source Type: research
Daily Aspirin No Longer Recommended To Prevent Heart Attacks In Older Adults
(CNN) — If you’re a healthy older adult looking for ways to reduce your risk of heart attack and stroke, don’t turn to that age-old standby: daily low-dose aspirin. It’s no longer recommended as a preventative for older adults who don’t have a high risk or existing heart disease, according to guidelines announced Sunday by the American College of Cardiology and the American Heart Association.
“For the most part, we are now much better at treating risk factors such as hypertension, diabetes and especially high cholesterol,” said North Carolina cardiologist Dr. Kevin Campbell, who wa...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 18, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News aspirin CNN Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
